Scarica l'app Stockscreener
7.73
4.74%
0.35
Dopo l'orario di chiusura:
7.73
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MYGN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.38
Aprire:
$7.38
Volume 24 ore:
1.31M
Relative Volume:
1.06
Capitalizzazione di mercato:
$720.54M
Reddito:
$823.60M
Utile/perdita netta:
$-116.00M
Rapporto P/E:
-5.9462
EPS:
-1.3
Flusso di cassa netto:
$-107.30M
1 W Prestazione:
+16.07%
1M Prestazione:
-5.15%
6M Prestazione:
+97.70%
1 anno Prestazione:
-50.10%
Intervallo 1D:
$7.315
$7.785
Intervallo di 1 settimana:
$6.43
$7.785
Portata 52W:
$3.76
$16.83
Myriad Genetics Inc Stock (MYGN) Company Profile
Nome
Myriad Genetics Inc
Settore
Industria
Telefono
801-584-3600
Indirizzo
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Confronta MYGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
7.73 | 687.92M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
586.07 | 220.72B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
226.98 | 160.62B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
752.14 | 57.96B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
153.60 | 42.88B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
228.18 | 38.30B | 15.90B | 1.28B | 2.21B | 7.2842 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-21 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-12 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | Iniziato | Craig Hallum | Buy |
| 2024-12-10 | Iniziato | UBS | Neutral |
| 2024-12-09 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-27 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-03 | Ripresa | Jefferies | Underperform |
| 2024-05-08 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | Ripresa | Piper Sandler | Neutral |
| 2023-12-19 | Iniziato | Wells Fargo | Equal Weight |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Underweight |
| 2023-05-23 | Aggiornamento | Goldman | Sell → Buy |
| 2023-01-18 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Iniziato | Stephens | Equal-Weight |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Sell |
| 2019-09-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Downgrade | Needham | Strong Buy → Hold |
| 2019-07-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2019-03-12 | Reiterato | Needham | Strong Buy |
| 2019-01-03 | Iniziato | Needham | Strong Buy |
| 2018-11-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Iniziato | Goldman | Sell |
| 2018-01-22 | Reiterato | Barclays | Equal Weight |
| 2018-01-05 | Iniziato | BTIG Research | Buy |
| 2017-10-02 | Ripresa | Leerink Partners | Mkt Perform |
| 2017-08-09 | Reiterato | Barclays | Equal Weight |
| 2017-02-08 | Aggiornamento | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Iniziato | Deutsche Bank | Sell |
| 2016-10-10 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
Mostra tutto
Myriad Genetics Inc Borsa (MYGN) Ultime notizie
Myriad Genetics joins Forbes list of America's dream employers for 2026 - Traders Union
Myriad Genetics Inc Stock Analysis and ForecastSmall Cap Stock Opportunities & Low Entry Cost Capital - earlytimes.in
Insulet, Guardant Health, agilon health, Evolent Health, and Myriad Genetics Stocks Trade Up, What You Need To Know - Yahoo Finance
Can Myriad Genetics Inc. stock sustain market leadershipMarket Activity Report & Real-Time Volume Spike Alerts - newser.com
Is Myriad Genetics Inc. (MYD) stock nearing a technical breakout2025 Key Highlights & Detailed Earnings Play Strategies - newser.com
Will Myriad Genetics Inc. stock benefit from sector rotationJuly 2025 Technicals & Entry Point Strategy Guides - newser.com
Why analysts upgrade Myriad Genetics Inc. stockJuly 2025 Big Picture & Technical Pattern Recognition Alerts - newser.com
Is Myriad Genetics Inc. (MYD) stock a buy on weaknessEarnings Growth Report & High Accuracy Swing Trade Signals - newser.com
Is Myriad Genetics Inc. (MYD) stock attractive for growth fundsMarket Activity Report & Growth Oriented Trade Recommendations - newser.com
How to use a screener to detect Myriad Genetics Inc. breakoutsPortfolio Value Summary & Stepwise Trade Execution Plans - newser.com
How Myriad Genetics Inc. (MYD) stock gains from tech spendingQuarterly Investment Review & Weekly Hot Stock Watchlists - newser.com
What’s the recovery path for long term holders of Myriad Genetics Inc.2025 AllTime Highs & Weekly Top Gainers Trade List - newser.com
Will Myriad Genetics Inc. (MYD) stock gain from lower interest ratesBond Market & Real-Time Stock Movement Alerts - newser.com
How Myriad Genetics Inc. (MYD) stock moves in volatile trading sessionsDay Trade & Safe Capital Preservation Plans - newser.com
What earnings revisions data tells us about Myriad Genetics Inc.Market Risk Report & Long-Term Growth Stock Strategies - newser.com
Why Myriad Genetics (MYGN) Stock Is Up Today - TradingView
Will Myriad Genetics Inc. stock beat EPS estimatesDollar Strength & High Return Trade Opportunity Guides - newser.com
Q3 Earnings Roundup: Myriad Genetics (NASDAQ:MYGN) And The Rest Of The Therapeutics Segment - Barchart.com
What momentum shifts mean for Myriad Genetics Inc.2025 Market WrapUp & Accurate Trade Setup Notifications - newser.com
Myriad Genetics at Wolfe Research: Strategic Shift in Cancer Care By Investing.com - Investing.com Canada
(MYGN) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Myriad Genetics Inc Azioni (MYGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.35%
1.41%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):